Cipla has received an approval to raise funds upto Rs 3000 crore by issue of non-convertible debentures (NCDs) (in form of bonds or otherwise) or bonds, whether denominated in Indian Rupee and/or foreign currency (ies), though a public issue or a private placement in accordance with the provisions of the applicable law. The Board of directors of the company at its meeting held on May 22, 2019 has approved for the same.
The company’s board also approved raising funds upto Rs 3000 crore by issue of equity shares or American depository receipts or global depository receipts or foreign currency convertible bonds or other securities/financial instruments convertible into equity shares, whether denominated in Indian Rupee and/or foreign currency (ies), though a public issue or a private placement in accordance with the provisions of the applicable law.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |